Related references
Note: Only part of the references are listed.Stroke Prevention with Hydroxyurea Enabled through Research and Education (SPHERE): a Phase 2 primary stroke prevention trial in sub-Saharan Africa
Luke R. R. Smart et al.
ACTA HAEMATOLOGICA (2023)
Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial
Shehu U. Abdullahi et al.
BLOOD (2023)
Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa
Peter Olupot-Olupot et al.
BLOOD (2023)
Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis
Zachary Baldwin et al.
PHARMACOECONOMICS-OPEN (2022)
Early hydroxyurea use is neuroprotective in children with sickle cell anemia
Kristine Karkoska et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Early initiation of disease-modifying therapy can impede or prevent diffuse myocardial fibrosis in sickle cell anemia
Omar Niss et al.
BLOOD (2022)
Hydroxyurea with Dose-Escalation to Reduce Primary Stroke Risk in Children with Sickle Cell Anemia in Tanzania: Primary Results of the Sphere Trial
Emmanuela E. Ambrose et al.
BLOOD (2022)
Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost
Enrico Costa et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Evolutionary history of sickle-cell mutation: implications for global genetic medicine
Kevin Esoh et al.
HUMAN MOLECULAR GENETICS (2021)
Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial
Shehu U Abdullahi et al.
Lancet Haematology (2021)
Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood
Andrew M. Heitzer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy
Arushi Dhar et al.
BLOOD ADVANCES (2021)
Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of theSPINtrial
Najibah A. Galadanci et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Hydroxycarbamide exposure and ovarian reserve in women with sickle cell disease in the Multicenter Study of Hydroxycarbamide
Lydia H. Pecker et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease
Laure Joseph et al.
BLOOD (2020)
Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa
Chandy C. John et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Real-world experience using hydroxyurea in children with sickle cell disease in Lilongwe, Malawi
Tisungane Mvalo et al.
PEDIATRIC BLOOD & CANCER (2019)
Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis
Michael R. DeBaun et al.
BLOOD (2019)
Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa
Leon Tshilolo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: A British Society for Haematology Guideline
Amrana Qureshi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia
Robert O. Opoka et al.
BLOOD (2017)
Hydroxyurea therapy in adult Nigerian sickle cell disease: a monocentric survey on pattern of use, clinical effects and patient's compliance
Ademola Samson Adewoyin et al.
AFRICAN HEALTH SCIENCES (2017)
Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial
Patrick T. McGann et al.
PEDIATRIC BLOOD & CANCER (2016)
Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis
Andreas Kuznik et al.
BMC HEALTH SERVICES RESEARCH (2016)
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
Russell E. Ware et al.
LANCET (2016)
Time to Invest in Sickle Cell Anemia as a Global Health Priority
Patrick T. McGann
PEDIATRICS (2016)
Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial
Juliana N. Anyanwu et al.
JMIR RESEARCH PROTOCOLS (2016)
Hydroxyurea therapy for sickle cell anemia
Patrick T. McGann et al.
EXPERT OPINION ON DRUG SAFETY (2015)
A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program for Sickle Cell Anemia in the Republic of Angola
Patrick T. McGann et al.
JOURNAL OF PEDIATRICS (2015)
Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis
Colette Cunningham-Myrie et al.
PEDIATRIC BLOOD & CANCER (2015)
Is Low Dose Hydroxyurea the Solution to the Global Epidemic of Sickle Cell Disease?
John J. Strouse
PEDIATRIC BLOOD & CANCER (2015)
Survival Among Children and Adults With Sickle Cell Disease in Belgium: Benefit From Hydroxyurea Treatment
Phu Quoc Le et al.
PEDIATRIC BLOOD & CANCER (2015)
Management of Sickle Cell Disease Summary of the 2014 Evidence-Based Report by Expert Panel Members
Barbara P. Yawn et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Proteinuria in adults with sickle-cell disease: the role of hydroxycarbamide(hydroxyurea) as a protective agent
Geraldo B. Silva Junior et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2014)
The effect of hydroxcarbamide therapy on survival of children with sickle cell disease
Clarisse Lopes de Castro Lobo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates
Frederic B. Piel et al.
LANCET (2013)
Hydroxyurea Is Associated With Lower Costs of Care of Young Children With Sickle Cell Anemia
Winfred C. Wang et al.
PEDIATRICS (2013)
Global Burden of Sickle Cell Anaemia in Children under Five, 2010-2050: Modelling Based on Demographics, Excess Mortality, and Interventions
Frederic B. Piel et al.
PLOS MEDICINE (2013)
Fetal haemoglobin levels and haematological characteristics of compound heterozygotes for haemoglobin S and deletional hereditary persistence of fetal haemoglobin
Duyen A. Ngo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Effect of hydroxyurea treatment on renal function parameters: Results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia
Ofelia Alvarez et al.
PEDIATRIC BLOOD & CANCER (2012)
Sickle Cell Disease in Africa A Neglected Cause of Early Childhood Mortality
Scott D. Grosse et al.
AMERICAN JOURNAL OF PREVENTIVE MEDICINE (2011)
Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia
Russell E. Ware et al.
BLOOD (2011)
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)
Winfred C. Wang et al.
LANCET (2011)
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up
Martin H. Steinberg et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)
Ersi Voskaridou et al.
BLOOD (2010)
Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis
Frederic B. Piel et al.
NATURE COMMUNICATIONS (2010)
Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea
Matthew Olnes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Exposure to Hydroxyurea and Pregnancy Outcomes in Patients With Sickle Cell Anemia
Samir K. Ballas et al.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION (2009)
A Pilot Study of Hydroxyurea to Prevent Chronic Organ Damage in Young Children With Sickle Cell Anemia
Courtney D. Thornburg et al.
PEDIATRIC BLOOD & CANCER (2009)
A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger
Rodwell Mabaera et al.
EXPERIMENTAL HEMATOLOGY (2008)
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease
SA Zimmerman et al.
BLOOD (2004)
Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells
M Brun et al.
PHARMACOGENOMICS JOURNAL (2003)
A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia
WC Wang et al.
JOURNAL OF PEDIATRICS (2001)
Exposure to hydroxyurea during pregnancy: a case series
C Thauvin-Robinet et al.
LEUKEMIA (2001)
Share Paper
